The clinical trial component of 3D Signatures’ (OTCQB:TDSGF; TSXV:DXD; FSE:3D0) Hodgkin's lymphoma test (Telo-HL) validation program is under way. This process is referred to as Stage 3 of the validation program.Read More
3D Signatures (TSXV:DXD; OTCQB:TDSGF; FSE:3D0) announced that clinical study results confirm that based on a swab from the inside of a patient’s cheek, its TeloView software platform has the ability to identify patients with Alzheimer’s disease (AD) and also distinguish between mild, moderate, and severe forms of the disease.Read More
3D Signatures (TSX-V:DXD) named Helen Stevenson to the board and Ian Smith, who is stepping down from the board, to the clinical and scientific advisory board (CSAB).Read More
3D Signatures (TSX-V:DXD) announced its participation in a major clinical trial for prostate cancer diagnosis and management, known as PRECISE, marking the company's first step toward validation and approval of clinical risk assessment tests for prostate cancer.
PRECISE is led by renowned uro-oncologist and prostate cancer thought leader, Dr. Laurence Klotz, who is chairman of the Canadian Urology Research Consortium, the study sponsor.Read More